Gyros named as 2006 Entrepreneurial Company of the Year

27-Oct-2006

Gyros announced today that it has been awarded Frost & Sullivan’s 2006 Drug Discovery Technologies Entrepreneurial Company of the Year Award, just 12 months after receiving the 2005 Excellence in Technology of the Year Award, also from Frost & Sullivan.

The Entrepreneurial Company of the Year Award is given to the company that has demonstrated superior entrepreneurial ability in its industry. The Award signifies the company’s identification of a unique and revolutionary product solution with significant market potential. In addition, the Award certifies that the company’s marketing strategy is sound and poised for success.

Founded in the year 2000, Gyros has leveraged its core capabilities in surface chemistries, microfabrication and system integration to develop a proprietary microfluidics platform for research, drug discovery/development and biopharmaceutical applications.

The company’s main commercial product, Gyrolab Bioaffy CD (compact disc) microlaboratory, is used together with Gyrolab® Workstation to provide a cost effective and automated solution for protein quantification at nanoliter scale. Scientists are able to use immunoassays with a very broad measuring range to generate more information from less sample, improving throughput and decreasing costs for labor and reagents.

Commenting on the award, Jan Würtz, CEO & President of Gyros AB said; “Everyone in the company has worked extremely hard to bring our unique technology to a position where it can really start to make an impact in the development of drugs and biopharmaceuticals. We have a strong intellectual property position and are continually exploring collaboration opportunities to expand our customer base and to develop new applications.”

“The Entrepreneurial Company of the Year award is a welcome endorsement of our marketing strategy, especially on the back of last year’s Technology of the Year Award”, added Mr. Würtz.

Details of Gyros award (PDF, 116.5 kB)

Download

 

About Frost & Sullivan Awards

Frost & Sullivan Awards are presented to companies in recognition of making an outstanding contribution to their respective industry or achieving a competitive or customer-based leading position in the market.

What is unique about Frost & Sullivan Awards?

This industry award is unique in that they are presented by a company dedicated to the analysis and forecasting of high-tech markets since its inception in 1961. Frost & Sullivan analysts conduct a rigorous selection methodology unmatched by any other firm.

What is the research methodology utilized in creating this award?

Entrepreneurial ability is assessed using mostly primary research with top manufacturers and end-users in the industry. Frost & Sullivan analyst teams perform extensive interviews with the company in question to evaluate its products, business, and marketing plan. In addition, primary research with leading manufacturers is performed to benchmark the award recipient’s strategy for growth against established players’ strategies. Also considered are elements such as strategic alliances, expected time to market, and the senior management team. Primary research with end-users is also conducted to evaluate and compare the value of the Award recipient’s product solution.

More information about Frost & Sullivan’s Awards Program: www.awards.frost.com


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.